Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country
- 1 August 2016
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 16 (8) , 453-459
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional CureJournal of the National Comprehensive Cancer Network, 2012
- The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsBlood, 2011
- Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapyBlood, 2009
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 2009
- How I treat chronic myeloid leukemia in the imatinib eraBlood, 2007
- Chronic myeloid leukaemiaThe Lancet, 2007
- Natural history and staging of chronic myelogenous leukemiaHematology/Oncology Clinics of North America, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999